Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

    AGBA

    MCap

    USD211m

    Last close

    USD2.83

    ▲ 0.48 (20.43%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Cereno Scientific (OMX: CRNO-B)

Last close As at 01/05/2024

SEK3.85

▲ −0.09 (−2.28%)

Market capitalisation

SEK1,083m

Based in Sweden, Cereno Scientific is focused on the development of innovative, effective and safe treatments for cardiovascular diseases (CVD) with unmet medical needs. Lead asset CS1, an HDAC inhibitor that acts as an epigenetic modulator, is currently being investigated in a Phase II clinical trial for the treatment of pulmonary arterial hypertension (PAH).

CVD encompasses various conditions implicated in the heart and blood vessels. Despite a growing repertoire of treatments, CVD is the most common cause of death worldwide. While rare, PAH is well-recognised, and disease-modifying therapies remain the holy grail in this indication. In a market dominated by vasodilators mainly offering symptomatic relief, CS1 claims disease-modifying potential underpinned by its epigenetic modulation properties.

Latest Insights

View More

Healthcare | Flash note

Cereno Scientific — CS014 (thrombosis) progresses towards the clinic

Healthcare | edison tv

Cereno Scientific – Executive interview with CSO and CMO

Healthcare | edison tv

Cereno Scientific – executive interview

Healthcare | Initiation

Cereno Scientific — Differentiated approach in CVD with potential
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • Eva Jagenheim

    CFO

  • Joakim Söderström

    Chairman

  • Sten Sörensen

    CEO

Balance Sheet

Forecast net cash (SEKm)

10.2

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (11.9) (21.4) 394.5
Relative (11.4) (27.3) 339.9
52 week high/low SEK5.3/SEK0.5

Financials

Cereno Scientific is a clinical-stage biotech, developing novel treatments for CVD. Lead asset, CS1, is an HDAC inhibitor aiming to deliver disease-modifying results in PAH. A Phase II study, leveraging Abbott’s CardioMEMS technology, is due to present top-line results in Q324. Interim updates, including the FDA-approved compassionate use programme, have been encouraging, in our view. Given the unmet need, we estimate blockbuster potential for CS1, contingent on successful clinical progress. Preclinical candidates include CS014 for thrombosis prevention without increased risk of bleeding, on track to enter the clinic within Q224. CS585 is being developed for CVD (specific indication not yet determined), with preclinical work set to continue throughout FY24. We value Cereno at SEK2.32bn (SEK9.9/share).

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2022A 0.0 (27.5) (27.6) (20.11) N/A N/A
2023A 0.0 (44.7) (48.2) (22.98) N/A N/A
2024E 0.0 (42.7) (51.2) (18.99) N/A N/A
2025E 0.0 (44.9) (48.6) (17.25) N/A N/A

Research

edison tv

Healthcare

Cereno Scientific – Executive interview with CSO and CMO

edison tv

Healthcare

Cereno Scientific – executive interview

Healthcare

Flash note

Cereno Scientific — CS014 (thrombosis) progresses towards the clinic

Thematics

thematic

Healthcare

Outlook for 2024: Life sciences – where has the conviction gone?

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare
volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways
View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free